Cal-Maine buys Van’s frozen breakfast brand

Cal-Maine Foods has acquired the Van’s frozen breakfast brand. The deal moves the US egg producer further into prepared foods, adding waffles, pancakes, and breakfast formats as protein, frozen bakery, and supply-chain diversification reshape the category.


IN Brief:

  • Cal-Maine Foods has acquired certain assets of Sara Lee Frozen Bakery’s Van’s Foods business.
  • The deal extends Cal-Maine’s prepared foods portfolio into frozen waffles, pancakes, and breakfast products.
  • The acquisition supports diversification beyond shell eggs as egg producers manage volatility, disease risk, and value-added food demand.

Cal-Maine Foods has acquired certain assets of Sara Lee Frozen Bakery’s Van’s Foods business, expanding the US egg producer’s presence in prepared foods and frozen breakfast.

The deal adds Van’s frozen waffles, pancakes, and related breakfast products to Cal-Maine’s portfolio. Van’s holds a leading position in gluten-free waffles and competes in the better-for-you frozen breakfast segment, with products spanning gluten-free, protein-enhanced, and whole-grain formats.

Cal-Maine is the largest shell egg producer in the United States and has been building a broader egg-based and prepared foods platform. The Van’s acquisition is expected to increase prepared foods annual sales by around 10% and volume by about 6% on a pro forma basis, while extending the company’s reach across grocery, e-commerce, and direct-to-consumer channels.

The diversification logic is clear. Shell eggs can be highly profitable, but they are exposed to disease risk, feed costs, market volatility, regulation, and consumer sensitivity to retail egg prices. Prepared foods offer a route into more stable, value-added categories, although they carry different manufacturing and brand-management demands.

Frozen breakfast production is a separate discipline from shell egg operations. Waffles and pancakes require batter systems, griddling or baking, freezing, packaging, cold storage, and distribution through temperature-controlled retail networks. Product consistency depends on ingredient functionality, moisture control, texture after reheating, pack integrity, and reliable frozen handling.

The category is also becoming more segmented. Gluten-free, protein-enhanced, whole-grain, and better-for-you products can support stronger positioning, but they also increase formulation complexity. Gluten-free batters require careful structure building; protein additions can affect texture and browning; and allergen management becomes especially important where products are aimed at consumers with dietary restrictions.

Prepared foods growth gives primary producers more ways to capture value downstream, but it also brings them closer to branded retail expectations. Cal-Maine will need to manage Van’s as a frozen bakery and breakfast platform, not simply as an extension of egg supply. Brand equity, cold-chain execution, product availability, and innovation cadence will all shape the value of the acquisition.

The deal also fits a wider pattern of upstream companies moving deeper into finished products. Ingredient and primary producers are increasingly using acquisitions to reduce exposure to commodity cycles and build customer relationships in more resilient categories. Those moves can strengthen revenue mix, but they also require stronger controls around traceability, allergen separation, recall management, and customer-specific specifications.

That interdependence has been visible in the downstream impact of California Dairies’ recall, where a supplier issue reached multiple processed food categories. As primary producers move further into prepared foods, the importance of integrated food safety data and supplier controls increases.

For Cal-Maine, Van’s gives the company a recognised brand in frozen breakfast and a larger prepared foods base. The opportunity now depends on how well the business combines egg-sector scale with frozen bakery manufacturing, brand stewardship, and reliable cold-chain execution.


Stories for you


  • EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 lowers LDL in clinical trial

    EPAX Cetoleic 2040 reduced LDL-cholesterol by 7% after eight weeks in a randomised clinical trial of overweight and obese adults, adding human data to the emerging category of marine long-chain monounsaturated fatty acids.


  • T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa targets dairy-free flavour gap

    T. Hasegawa USA has launched HASEMILK, a powdered dairy-free flavour technology designed to recreate milk taste, aroma, and mouthfeel in plant-based beverages, bakery, desserts, sauces, and dry mixes.